The object of this study was to evaluate the suitability of the Neogen Corp. microtiter plate enzyme.linked immunoassays (ELISA) for the screening of postmortem blood for amphetamine and methamphetamine and to choose the more appropriate assay for screening. Forty-seven postmortem whole blood specimens were obtained from drug-involved deaths, which had been screened and confirmed positive for methamphetamine and/or amphetamine. Eighty.five negative specimens were obtained from non-amphetamines-involved deaths, 17 of which involved decomposition. Specimens were tested using the Neogen Amphetamine Ultra and Neogen Methamphetamine/MDMA microtiter plate ELISA assays. No matrix effects were found for whole blood in these assays, and a dilution of 1:5 was chosen to facilitate pipetting and to bring the IC50 of the microtiter plate ELISA assay within the range of amphetamines concentrations encountered in medical examiner specimens. True positives, true negatives, false positives, and false negatives were determined relative to gas chromatography-mass spectrometry (GC-MS) and graphed for the ELISA. From these graphs and the receiver operating curves (ROC), the optimal cut-off for the Neogen Methamphetamine/MDMA ELISA was 50 ng/mL methamphetamine equivalents and the optimum cut-off for the Neogen Amphetamine Ultra ELISA was 100 ng/mL amphetamine equivalents. The Neogen Methamphetamine ELISA had a sensitivity of 93.6% + 3.5% and a specificity of 77.6% _+ 4.5% versus GC-MS at the cut-off of 50-ng/mL methamphetamine equivalents. The Neogen Amphetamine Ultra ELISA had a sensitivity of 95.7% _+ 3.0% and a specificity of 72.9% -+ 5.2% versus GC-MS at the 100-ng/mL amphetamine equivalents cut-off. The areas under the ROCs were equivalent for the two ELISA assays.
Introduction
The object of this study was to evaluate the suitability of the Neogen Corp. (Lexington, KY) microtiter plate enzyme-linked immunoassays (ELISA) for screening of postmortem blood for amphetamine and methamphetamine and to choose the more appropriate assay for screening. Two assays are available from Neogen, the Amphetamine Ultra ELISA and the Methamphetamine/MDMA ELISA. The Methamphetamine/MDMA assay has substantial cross-reactivity with methylenedioxymethamphetamine (MDMA, Ecstasy) as well as methamphetamine but not amphetamine (Table I) . Although the Amphetamine Ultra assay has good cross-reactivity with methamphetamine, it does not cross-react substantially with MDA or MDMA (Table I) . A number of cases with other sympathomimetic amines such as over-the-counter cold remedies were included to determine the relative specificity of these assays in screening postmortem blood. The assays were also tested to determine their susceptibility to false positives in decomposed specimens due to crossreactivity with ~-phenethylamine.
Methods

Specimens
Seventy-eight postmortem specimens that screened positive by the laboratories' current microtiter plate enzyme immunoassay (OraSure Technologies, Bethlehem, PA) were selected as indicated in Table I . An additional 52 specimens were selected from cases confirmed negative by gas chromatography-mass spectrometry (GC-MS), gas chromatography-nitrogen-phosphorus detection, or gas chromatography-flame-ionization detection for amphetamines. NaF was added to the whole blood specimens at approximately 1% concentration.
Specimen dilution
Whole blood standards were prepared by spiking an appropriate amount of methamphetamine or amphetamine in solution into a certified negative whole blood pool. The negative blood pool was obtained by pooling blood from Medical Examiner cases that had screened negative. The standard concentrations were 0, 5, 10, 25, 50, 75, and 100 ng/mL amphetamine or methamphetamine. Whole blood specimens and standards were diluted 1:5:50 ~L whole blood to 200 p~L EIA buffer from Neogen.
Neogen microtiter plate assays
Microtiter-plate-based Neogen Amphetamine Ultra ELISA and Neogen Methamphetamine/MDMA ELISA were evaluated. In addition to the spiked whole blood calibration standards and specimens, the manufacturer's EIA standard, and negative and positive synthetic-urine-based controls were run on each plate. Diluted samples (20 I~L) were pipetted manually into the microtiter plate wells in duplicate. The ELISAs were then run according to the manufacturers' instructions. Diluted drug-enzyme conjugate was added to the microtiter plate wells, and the mixture incubated at room temperature for 45 min. After incubation, the plate was washed five times with wash buffer (phos- Calibration curves were plotted as log concentration versus the logit of the ratio of the mean absorbance at each concentration divided by the mean absorbance of the zero standard (B/Bo). The methamphetamine or amphetamine equivalents were estimated from the calibration curve using the ratio of the mean absorbance of the specimen to the mean absorbance of the zero standard.
Precision
Intra-assay precision was determined from 40 replicate analyses of the 1:5 dilution of the 50-ng/mL methamphetamine standard and 40 replicates of the 100-ng/mL amphetamine standard. Interassay precision was calculated from the absorbances for the concentration standards and controls run at the beginning and end of each microtiter plate experiment.
Methamphetamine/amphetamine by GC-MS
GC-MS was used to confirm the presence of methamphetamine and/or amphetamine using a modification of a previously published method (1). Unless otherwise specified, all solvents were reagent grade or better. One milliliter of concentrated ammonium hydroxide and 0.5 lag of internal standard (npropylamphetamine, Alltech) were added to 2.0 mL blood. Nine milliliters of 1-chlorobutane was added to test tubes then rotoextracted for 10 rain and centrifuged for 5 rain at 2000 rpm. The upper organic layer was transferred to a 15-mL glass culture tube, and 2.0 mL 1N sulfuric acid was added. The tubes were roto-extracted for 10 rain and centrifuged at 2000 rpm for 5 rain. The upper organic layer was aspirated to waste and 1.0 mL 6N sodium hydroxide was added to the acid layer along with 3.0 mL of 1-chlorobutane. The tubes were roto-extracted for 10 rain and centrifuged for 5 rain at 2000 rpm. The upper organic layer was transferred to a 5.0-mL glass conical tube, and 50 pL pentafluorpropionic anhydride (PFPA, Sigma Chemical) was added. The tubes were vortex mixed and placed in a 90~ heating block for 30 rain. The solvents were then evaporated under nitrogen, in a 40~ water bath, to dryness. The residue was reconstituted with 50 gL ofn-propanol, and the extract was transferred to an autosampler vial.
The samples were analyzed using an HP-5970 GC-M8 (Hewlett-Packard) equipped with a capillary column (HP-1, 12 m x 0.2 mmx 0.33 mm). The initial oven temperature of 80~ was ramped to 180~ at a rate of 10~ The temperature was then ramped from 180~ to 300~ at 40~ Selected ion monitoring was used with the following ions being monitored (the first ion listed was used for quantitation): 204, 160, 118 for methamphetamine; 190, 118, 91 for amphetamine; and 232, 190, 118 for n-propylamphetamine. Phentermine (204, 132, 164), pseudoephedrine (204, 160, 119), methylene-dioxymethamphetamine (204, 162, 160), and fenfluramine (218, 190, 159) were also monitored with this method. The identification of each analyte was based upon retention time match and ion ratios within 20% of controls. The assay was linear from 0.01 to 2.0 ~g/mL, and the limit of detection for each of the analytes was 10 ng/mL.
Probability analysis
The number of true positives, false negatives, false positives, and true negatives was determined for nine possible methamphetamine or amphetamine cut-off concentrations ranging from 5 to 250 ng/mL methamphetamine or amphetamine equivalents by comparison with GC-MS results.
Sensitivity, specificity, and predictive value
Sensitivity, the true positive rate, was calculated from the tally of true positives and false negatives determined as Sentitivity = TP/(TP + FN). Specificity was calculated as Sensitivity = TN/(TN + FP). Because sensitivity and specificity are probabilities, the standard error (SEp) is equal to SEp = square root
Receiver operating curves (ROC) were obtained by plotting the sensitivity at each putative cut-off concentration versus (1 -specificity) at that cut-offvalue (2). The positive predictive value was calculated as fp/[t~ + (1 -f)(1 -q)] where f is the prevalence in the population to be tested, p is the sensitivity, and q is the specificity.
Results
Precision
The intra-assay precision of the Neogen Methamphetamine/ MDMA ELISA for 40 replicates of spiked whole blood at 50 ng/mL methamphetamine was calculated from the absorbance with a mean optical density (OD) 0.425 • 0.0019 SD for a % CV of 0.4%. The intra-assay precision of the B/B o ratio had a mean of 57.6 • 1.19 (2.06% CV)and for estimated concentration, the mean was 54.0 ng/mL • 3.86 ng/mL (7.1% CV). The interassay precision of the ratio of the absorbance of the 50-ng/mL calibrator to that of the zero whole blood calibrator (B/B0) had a mean of 55.8 + 1.55 SD or a % CV of 2.77% (n = 5). The absorbance for the calibrators was also very stable and repeatable. For example, the 50-ng/mL calibrator had a mean optical density of 0.467 _ 0.046 (9.85% CV, n = 5). The data for interassay precision was taken from five different runs performed over a three-month period. The interassay coefficients of variation were calculated from the B/Bo ratios of the whole blood calibrators run in each assay for methamphetamine, which ranged from 7.12 to 10.35%. The interassay precision calculated from the B/B o ratios of the positive urine controls run in each assay had a mean of 4255 ng/mL • 2045 ng/mL, range 2225-7688 ng/mL (n = 5, 48% CV) for the methamphetamine assay. This large % CV demonstrates that extended estimation of concentrations above the range of the calibration curve is unreliable. The positive control was always positive, and the negative urine control was always negative.
The intra-assay precision of the Neogen Amphetamine Ultra ELISA for 40 replicates of spiked whole blood at 100 ng/mL amphetamine was calculated from the absorbance and had a mean OD 0.169 • 0.020 SD for a % CV of 12.1%. The intraassay precision of the B/B o ratio had a mean of 23.77 • 1.84 (7.75% CV) and for estimated concentration, the mean was 91.7 ng/mL • 16.3 ng/mL (17.8% CV). The interassay precision of the ratio of the absorbance for the 100-ng/mL calibrator to that of the zero whole blood calibrator (B/B0) had a mean of 20.3 _ 3.8 or a 18.5% CV. The data for interassay precision was taken from five different runs performed over a three-month period. The interassay precision of the B/B o ratio for the controls had a mean of 88.3% + 4.76 %, 5.4% CV (negative control) and 7.2% • 1.76%, 24.5% CV (positive control). The precision of the concentrations calculated from the B/B o ratios of the whole blood calibrators run in each assay for amphetamine ranged from 4.8 to 18.5% (n = 5). The interassay precision of the concentration calculated from the B/B o ratios of the positive urine control run in each assay had a mean 982.8 ng/mL _ 1062 ng/mL (n = 5, 108% CV) for amphetamine. The plates were manually pipetted.
Case results
The ELISA results, estimated as methamphetamine or amphetamine equivalents, and the GC-MS values for the methamphetamine-and/or amphetamine-involved deaths are shown in Table II . By comparing the ELISA result with the GC-MS results as reference, the true-positive, false-negative, false-positive, and true-negative values at putative cut-off concentrations were calculated. These are shown in Figure i for the methamphetamine assay and in Figure 2 for the amphetamine assay for cut-offs 5-250 ng/mL methamphetamine or amphetamine equivalents. From the graphs it can be seen that the optimum cut-off concentration is 50 ng/mL methamphetamine equivalents for the Neogen Methamphetamine/MDMA ELISA and 100 ng/mL amphetamine for the Neogen Amphetamine Ultra ELISA.
ROC analysis
From the true-positive rate and false-negative rate, the sensitivity of each assay was determined at each cut-off concentration. From the true-negative rate and the false-positive rate, the specificity was calculated at each cut-off concentration. The sensitivity was plotted versus 1 -specificity for each cut-off concentration value to give a relative operating characteristic curve (ROC). The ROC curves for both ELISAs on postmortem whole blood are shown in Figure 3 . Using a cut-off of 50 ng/mL, the Neogen Methamphetamine/MDMA ELISA has a sensitivity of 93.6% and specificity of 77.6%. Utilizing a cut-off of 100 ng/mL, the sensitivity drops to 87.2% and the specificity raises to 82.4%. A large part of the false-positive results are due to cross-reactivity with 13-phenethylamine. If the known decomposed specimens are removed from the analysis, the sensitivity of the Neogen Methamphetamine/MDMA ELISA at a cut-off of 50 ng/mL is 93.6% and specificity is 97.0%. Over-the-counter sympathomimetic amines (pseudoephedrine, six cases; diphenhydramine, three cases) account for most of false positives when decomposed specimens are removed from the analysis.
The ROC curve for the Neogen Amphetamine Ultra ELISA on postmortem whole blood is shown in Figure 3 . The optimum cut-off concentration for this assay is 100 ng/mL amphetamine equivalents. At a cut-off of 100 ng/mL, the Neogen Amphetamine Ultra ELISA has a sensitivity of 95.7% and a specificity of 72.9%. If the decomposed specimens are removed from the analysis, at a cut-off of 100 ng/mL, the sensitivity is 95.7% and the specificity 94.7%. These values with their standard errors are shown in Table III . The areas under the ROC curves for the two ELISAs were equivalent (Figure 3) , and therefore, the ELISAs were equally accurate for identification of amphetamines in this sample population (2,3).
Discussion
The cross-reactivities for Neogen Methamphetamine/MDMA ELISA and Neogen Amphetamine Ultra ELISA shown in Table  I were confirmed by the results of the study. The positive predictive value of a positive result with the Neogen Methamphetamine/MDMA ELISA depends on the prevalence of decomposed specimens in the screened population. These assays have precision and accuracy better than or comparable to the currently used EIA and previously published microtiter plate screening immunoassays (4) (5) (6) (7) (8) .
The assays identified the presence of amphetamines in the postmortem blood specimens with less interference from sympathomimetic amines than the currently used microtiter plate EIA. The concordance between the currently used amphetamines EIA and the Neogen Amphetamine Ultra ELISA assay was 89.5% and with the Neogen Methamphetamine/ MDMA ELISA was 87.7%. In general, the amphetamines EIA had more false positives than the Neogen ELISAs. Of the 17 discrepant results between the Neogen Methamphetamine/MDMA ELISA and the current amphetamines EIA, I was a false negative by EIA (according to the GC-MS) and 16 were EIA false positives (according to GC-MS); most were in specimens from decomposed bodies. Comparing the 17 discrepant results between Neogen Amphetamine Ultra ELISA and the Amphetamines EIA, 1 was an EIA false negative and 13 were EIA false positives by GC-MS.
The two Neogen ELISAs were equally accurate for identification of amphetamines in this sample population. The final choice of an assay will depend on the abuse profile in the screened population. If amphetamine is encountered as a drug of abuse in and of itself rather than just as a metabolite of methamphetamine, then Neogen Amphetamine Ultra assay would be the assay of choice. If the abuse profile of the screened population is methamphetamine and MDMA with amphetamine encountered mainly as a metabolite of methamphetamine, then the more precise and specific Neogen Methamphetamine/MDMA would be the assay of choice.
